Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07831473) titled 'Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults' on Sept. 15.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: VLP Therapeutics
Condition:
Randomised Clinical Trial
Double Blind
Dengue
Challenge Test
Dose Escalation and Safety
Intervention:
Biological: VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant
Biological: VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant
Biological: VLPDEN-02 100 µg (25 µ...